Recent Updates
Recently added Catalysts

Nesuparib

Phase 2

Endometrial Cancer | Small Molecules | Oncology |Merck & Company, Inc.|Trials Updated: Nov 16, 2026

Nesuparib development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Jul 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment92

FDA Designations

No designations recorded

Nesuparib clinical trials

Nesuparib · 1 trial · 5 indications

Phase 2 1
NCT06502743First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial CancerEndometrial Cancer
RECRUITING92 Analytics
PHASE2RECRUITING
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
Endometrial CancerUnlock trial analytics

Study Endpoints

Primary Endpoints

Dose-limiting toxicities
Assessed during 21days from day 1 of first combination maintenance treatment cycle (i.e., 21 days of Cycle 8 from day 1)

In Part A, To evaluate dose-limiting toxicities(DLTs) of combination maintenance treatment with pembrolizumab and nesuparib during the 21 days from first nesuparib and pembrolizumab administration, and to establish a recommended Phase 2 dose(RP2D) and dosing schedule.

Overall distribution of progression-free survival
Approximately 11.01 months

The time from randomization to the time when Progressive disease(PD) is first confirmed after administration of the first investigational drug (Pembrolizumab) or until death without disease progression.

Secondary Endpoints

3, 6, 9 12-month Progression-free rate(PFS rate)
3month, 6month, 9month, 12month after the study enrollment
Median Progression-free time(Median PFS time)
All 36 subjects in each groups are enrolled and the 18-month follow-up period ends
Overall response rate(ORR)
All 36 subjects in each groups are enrolled and the 18-month follow-up period ends
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part B - Pembrolizumab monotherapyEXPERIMENTALChemotherapy Treatment Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day 1 + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks Maintenance Treatment Pembrolizumab 400 mg IV Day 1 x up to 14 cycles (o ne cycle = 6 weeks ) Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + maintenance Treatment ) = 20
Part B - Pembrolizumab and nesuparib combination therapyEXPERIMENTALCombination therapy Chemotherapy Treatment Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks) Maintenance Treatment Pembrolizumab 400 mg IV Day 1 + Nesuparib 150mg or 100mg QD PO x up to 14 cycles (o ne cycle = 6 weeks ) Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + maintenance Treatment ) = 20
Part A - Safety Run-in PhaseEXPERIMENTALChemotherapy Treatment: Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day 1 + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks) Maintenance Treatment: Pembrolizumab 400 mg IV Day 1 + Nesuparib 150mg or 100mg QD PO x up to 14 cycles (one cycle = 6 weeks) Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + Maintenance Treatment) = 20

Interventions

NameTypeDescription
NesuparibDRUGNesuparib 150mg or 100mg, QD, PO
PembrolizumabDRUGPembrolizumab 400mg, IV, Q6W
Unlock Study Design Details

Eligibility Criteria

Age Range19 Years to N/A
SexFEMALE
Healthy VolunteersNo
Study Sites8

\[Inclusion Criteria\] 1. Patient must be female ≥ 19 years of age 2. Histologic confirmation of the original primary tumor is required. Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcino...

Countries:South Korea
Unlock Eligibility Criteria